Core Viewpoint - Researchers from South China Agricultural University and Henan University of Science and Technology have discovered a new mechanism for selenium transport in rice, providing a theoretical basis for increasing the selenium content in rice and guiding the development of new selenium-rich rice varieties [1][2]. Group 1: Selenium's Importance and Current Challenges - Selenium is an essential trace element for humans, playing a crucial role in enhancing immunity, antioxidant activity, and cancer prevention. A lack of selenium can lead to various health issues, including heart disease and cancer [1]. - Approximately 700 million people in China live in selenium-deficient or low-selenium areas, posing a potential risk for insufficient selenium intake [1]. - Rice, a staple food for half of the global population, generally has low selenium content, primarily in the form of selenomethionine, which is less efficiently absorbed by the human body compared to methylselenocysteine, a more bioavailable form of selenium found in vegetables like broccoli and garlic [1]. Group 2: Research Findings - The study identified a transport protein named NRT1.1B in rice, which functions as a "selenium courier," transporting high-quality selenium from the roots to the stems and leaves during the growth period, and back to the roots for temporary storage [2]. - During the grain-filling stage, this transport protein plays a critical role in efficiently delivering high-quality selenium from the roots and leaves to the developing grains [2]. - The goal of the research is to ensure that every grain of rice can better meet human selenium needs, with plans to further develop these findings into products that provide rice rich in methylselenocysteine [2].

1. 金融资产公允价值变动"粉饰"利润 6月4日，四川证监局发布公告，对北京厚鸿科技有限责任公司（以下简称"厚鸿科技"）采取出具警示函 的行政监管措施，并记入证券期货市场诚信档案。 2024年1月，汇宇制药公告拟向子公司汇宇悦迎提供不超过6000万元的财务资助，厚鸿科技作为汇宇悦 迎持股39.9%的股东，承诺按比例提供资助。厚鸿科技是汇宇制药实际控制人丁兆直接控制的企业。根 据公告，厚鸿科技与成都厚汉均为丁兆控制的关联方 截至2024年8月15日，汇宇制药已提供2200万元资助，但厚鸿科技未履行承诺，构成《上市公司监管指 引第4号》第15条违规。 此外，实控人亲属涉短线交易遭监管批评。丁兆父母于2021-2023年频繁买卖公司股票，成交额281万 元，构成"买入后6个月内卖出"违规行为，丁兆因此被上交所通报批评。 业绩增长的表象与驱动力：非经常性损益主导下的"伪高增"？ 汇宇制药2024年财报数据显示，其营业收入10.9亿元（同比+18.05%）、净利润3.25亿元（同比 +132.78%），表面呈现爆发式增长。然而，扣除非经常性损益后的净利润仅0.92亿元（同比 +39.55%），暴露业绩增长的脆弱性。核心 ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 众所周知，人体的蛋白质由 20 种氨基酸组成，其中 9 种是 必需氨基酸 —— 异亮氨酸、亮氨酸、赖氨酸、甲硫氨酸、苯丙氨酸、苏氨酸、色氨酸、缬氨酸和 组 氨酸，人体无法自行合成这些氨基酸，因此需要通过饮食补充 （组氨酸比较特殊，婴幼儿其无法合成，成年人可部分合成） 。值得注意的是，在胱硫醚γ裂解酶 （CSE） 或胱硫醚β合酶 （CBS） 突变的动物无法自行合成半胱氨酸，因此， 半胱氨酸 也是它们的必需氨基酸。 已有大量研究检查了在饮食中去除单个必需氨基酸的影响，揭示了它们在代谢、能量消耗以及体重和脂肪减少中的作用。此外，还有研究显示， 在饮食中限制甲 硫氨酸和半胱氨酸，在动物模型中能够延长寿命、预防代谢疾病 。但尚不清楚这些益处究竟是限制甲硫氨酸驱动的还是限制半胱氨酸驱动的。 2025 年 5 月 21 日，国际顶尖学术期刊 Nature 在其官网头条报道了一项重磅研究成果—— 缺乏这种氨基酸的小鼠，体重减轻了 30% 。这一体重下降比例超过 当前效果最好的减肥药物 替尔泊肽 在临床试验中的效果 （72周时平均减重 20%） 。 半胱氨酸 （C ysteine） 是一 ...

证券代码：301096 证券简称：百诚医药 杭州百诚医药科技股份有限公司 投资者关系活动记录表 编号：2025-001 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他（电话） 参与单位名称及 人员姓名 投资者网上提问 时间 2025 年 5 月 15 日 (周四) 下午 16:00~17:00 地点 公 司 通 过 进 门 财 经 （https://s.comein.cn/fchgkrsp）采用网络互动的 方式召开业绩说明会 上市公司接待人 员姓名 1、董事长兼总经理楼金芳 2、董事、财务总监兼董事会秘书程丹丹 3、独立董事黄志雄 4、国金证券保荐代表人耿旭东 投资者关系活动 主要内容介绍 投资者提出的问题及公司回复情况 公司就投资者在本次说明会中提出的问题进行了回复： 1、美国降低医药售价，有机构预测为了降低成本，国 外药企的研发业务会更多的给到中国，请问百诚医药有国际 营销部吗，是否接过国外的研发业务？ 您好，公司有国际营销部负责国际业务，目前主要负责 原料药和制剂的出口销售。后续如有合适的国外研发服务订 单，公司会积极拓展相应的海 ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 铁死亡 （ ferroptosis） 是一种新型 程序性细胞死亡形式， 其生化特征及遗传调控通路显著区别于细胞凋 亡、坏死及自噬，核心标志为细胞内铁离子异常蓄积与活性氧 （ROS） 爆发性生成，导致细胞膜的脂质过 氧化。 近年来的 许多研究显示，铁死亡与包括癌症、神经退行性疾病在内的多种疾病有关，成为多种疾病的潜在 治疗靶点，引起了科学界的广泛关注。 N -乙酰- L -半胱氨酸 （NAC） 是一种药物，也是细胞死亡研究中广泛使用的抗氧化剂。尽管其作用机制 有些模糊，但其在抑制铁死亡方面的作用正日益受到认可。 2025 年 4 月 30 日，铁死亡研究先驱、德国亥姆霍兹慕尼黑研究中心/慕尼黑工业大学 Marcus Conrad 教授团队 （ 郑嘉烁 、 张唯佳 为共同第一作者） 在 Cell 子刊 Cell Chemical Biology 上发表了题为： N -acetyl- l -cysteine averts ferroptosis by fostering glutathione peroxidase 4 的论文。 该研究加深了我们对 NAC 作为铁死亡抑制剂的 ...

Core Viewpoint - Tianjin Pharmaceutical Industry is recognized as a leading domestic manufacturer of steroid hormone drugs and a global leader in amino acid raw materials, showcasing its advanced position and demonstration effect in the industry for the year 2024 [1] Product Matrix - The company has a diverse product matrix with over 70 types of raw materials, including dexamethasone series, prednisone series, methylprednisolone series, betamethasone series, and amino acids, as well as more than 10 dosage forms such as injections, ointments, and tablets, catering to various patient treatment needs [2] R&D Innovation - In recent years, the company has significantly enhanced its product R&D and scientific research system, focusing on steroid hormones and amino acids, and implementing a "raw materials + formulations" full industry chain layout, with R&D investment reaching 248 million yuan in 2024, accounting for 7.7% of revenue, reflecting its strong R&D capabilities [3] Dual-Track Strategy - The company employs a dual-track strategy of "innovation line" and "generic line" to accelerate the new drug approval process, with 11 specifications of 10 products recently receiving approval, including the first domestic approval for a specific injection by its subsidiary [4] Market Performance - Among its products, the injection of isopropyl methochloride has shown strong market performance, with sales increasing from 756 million yuan in 2022 to 821 million yuan in 2023, and is expected to expand further due to its inclusion in the national medical insurance [5] - The inhalation solution of acetylcysteine is also a national medical insurance drug, with significant market potential in treating respiratory diseases, indicating a stable growth outlook as the patient population expands [5] Future Outlook - The company plans to continue its commitment to innovation, increasing investment in technology R&D, and focusing on new product development and consistency evaluation to provide high-quality, efficient drugs for patients and deliver substantial value returns to shareholders [6]

Core Viewpoint - Chengyi Pharmaceutical reported significant growth in revenue and net profit for 2024 and Q1 2025, highlighting its strategic focus on marine biomedicine and integrated drug production [1] Financial Performance - In 2024, the company's revenue reached 714 million yuan, a year-on-year increase of 6.36%, while the net profit attributable to shareholders was 201 million yuan, reflecting a substantial growth of 23.21% [1] - For Q1 2025, revenue was 186 million yuan, showing a year-on-year growth of 21.26%, and net profit was 45.79 million yuan, up 40.10% compared to the previous year [1] - The company plans to distribute a cash dividend of 2.5 yuan per 10 shares, totaling approximately 79.42 million yuan, alongside a share buyback of 67.26 million yuan, amounting to a total of 147 million yuan, which represents 73.09% of the net profit [1] Product and Market Development - Revenue from joint disease medications in 2024 was 502 million yuan, marking a year-on-year increase of 23.41%, with Q1 2025 revenue at 143 million yuan, a significant rise of 49.62% [1] - Chengyi Pharmaceutical is the first listed company in Zhejiang Province focusing on marine biomedicine, with its core product, glucosamine hydrochloride, sourced from chitin derived from crab and shrimp shells, establishing itself as a major supplier in China [1] - The company has six domestic health food products, with the new "Haicuiwei Fish Oil Soft Capsule" expected to complete registration and launch by December 2024 [1] Strategic Initiatives - Chengyi Pharmaceutical is actively developing a production capacity project for 1,000 tons of super fish oil EPA and is pushing for the application of new drugs such as EPA soft capsules [1] - During the reporting period, several products, including lidocaine injection and amikacin sulfate injection, passed consistency evaluations, while new products like calcitriol soft capsules and levocarnitine injection received approval [1] - The company aims to focus on four major industrial sectors and deepen its integrated strategy of "raw materials + formulations" [1]